Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw an uptick in trading volume on Friday . 6,325 shares traded hands during trading, an increase of 63% from the previous session’s volume of 3,885 shares.The stock last traded at $24.74 and had previously closed at $25.00.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. BTIG Research initiated coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective for the company. Piper Sandler began coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat.com, Ascentage Pharma Group International has an average rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The firm has a fifty day simple moving average of $28.49 and a 200-day simple moving average of $34.87.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of AAPG. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth $383,000. XY Capital Ltd grew its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International during the third quarter worth about $204,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth about $96,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.